DAAOI-1 Treatment for Treatment-resistant Schizophrenia
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative
symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia
(particularly clozapine-resistant) is still a difficult clinical issue at present. According
to the N-methyl-D-aspartate (NMDA) hypothesis, adjuvant NMDA-enhancing agents may have
therapeutic benefit. DAAOI-1, a D-amino acid oxidase (DAAO) inhibitor, is a NMDA-enhancing
agents.
The aim of this project is to examine the effectiveness and safety of DAAOI-1 adjuvant
treatment for clozapine-resistant refractory schizophrenia patients in a randomized,
double-blind, placebo - controlled trial.
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University Hospital
Collaborator:
Department of Health, Executive Yuan, R.O.C. (Taiwan)